Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.40 |
| ▸ | PDE4A | P27815 | 9/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221383 | 1.00 | MAPK8 (0.41) | MAPK8MAPK9PDE4DPDE4APDE4B | |
| SCHEMBL28779932 | 0.86 | MAPK8 (0.40) | MAPK8MAPK9PDE4DPDE4APDE4B | |
| SCHEMBL28779927 | 0.86 | MAPK8 (0.40) | MAPK8MAPK9PDE4DPDE4APDE4B | |
| SCHEMBL28868070 | 0.85 | PDE4D (0.51) | MAPK8MAPK9PDE4DPDE4APDE4B | |
| SCHEMBL28868065 | 0.85 | PDE4D (0.51) | MAPK8MAPK9PDE4DPDE4APDE4B | |
| SCHEMBL4225630 | 0.82 | PDE4A (0.40) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL7226064 | 0.81 | PDE4D (0.38) | PDE4DPDE4APDE4BPDE4CSYK | |
| SCHEMBL6989382 | 0.81 | PDE4D (0.38) | PDE4DPDE4APDE4BPDE4CSYK | |
| SCHEMBL1672509 | 0.77 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CSYK | |
| SCHEMBL24735855 | 0.76 | KDM4E (0.61) | MAPK8MAPK9PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656946-B2 | For treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
| EP-1315705-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM ZENTRALE GMBH (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | US | disclosed |
| WO-2002018351-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082271-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K19, MAP3K20 | MAPK8 95/4885MAPK9 64/4885PDE4D 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.